Inhibrx Biosci 
Welcome,         Profile    Billing    Logout  
 5 Products   2 Diseases  5 Products   9 Trials   61 News 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SAR447537 / Sanofi
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Active, not recruiting
2
99
Europe, US, RoW
SAR447537, Zemaira, Respreeza
Sanofi
Alpha 1-Antitrypsin Deficiency, Emphysema
08/25
10/25
ELEVAATE OLE, NCT05897424: Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Recruiting
2
130
Europe, US, RoW
SAR447537
Sanofi
Alpha 1-Antitrypsin Deficiency, Emphysema
06/28
09/28
ozekibart (INBRX-109) / Inhibrx Biosci
2021-002635-35: A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarcoma). Estudio de fase 2, de INBRX-109 en adultos en un tipo de cancer de huesos y articulaciones irresecable o metastasico (condrosarcoma convencional)

Not yet recruiting
2
201
Europe
Desametasone, Difenidramina, INBRX-109, INBRX-109, Lyophilisate for solution for infusion
Inhibrx, Inc., Inhibrx, INC, Inhibrx, Inc.
Unresectable or metastatic conventional chondrosarcoma condrosarcoma convencional irresecable o metastásico., Malignant bone tumor that cannot be resected or it has been spread from the primary site (place where it started) to other places in the body. Tumor óseo maligno que no puede ser resecado o que se ha extendido desde el sitio primario (lugar donde comenzó) a otros lugares del cuerpo., Diseases [C] - Cancer [C04]
 
 
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
enristomig (INBRX-105) / Inhibrx Biosci
NCT03809624: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Terminated
1
160
US
INBRX-105 - PDL1x41BB antibody, Pembrolizumab, Keytruda
Inhibrx Biosciences, Inc
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
10/24
10/24
INBRX-106 / Inhibrx Biosci
HexAgon-HN, NCT06295731: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Recruiting
2/3
410
Europe, US, RoW
INBRX-106, Hexavalent OX40 agonist antibody, Pembrolizumab, Keytruda
Inhibrx Biosciences, Inc
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/29
05/29
NCT06353997: Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

Recruiting
2
12
US
Pembrolizumab, KEYTRUDA, INBRX-106
Providence Health & Services, Inhibrx Biosciences, Inc
Triple Negative Breast Cancer
06/27
06/29
NCT06623136: A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Recruiting
2
40
RoW
ES102, Toripalimab
Elpiscience (Suzhou) Biopharma, Ltd.
Non-Small Cell Lung Cancer
02/27
12/27
KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting
1/2
333
US
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, KEYTRUDA, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Alimta®, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2
Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
02/26
05/26
NCT04730843: A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors

Completed
1
18
RoW
ES102
Elpiscience Biopharma, Ltd.
Solid Tumors, Neoplasms, Malignant Tumor
03/24
03/24
NCT04991506: A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Completed
1
30
RoW
ES102, JS001, Toripalimab
Elpiscience Biopharma, Ltd., Shanghai Junshi Bioscience Co., Ltd.
Solid Tumor, Neoplasms, Malignant Tumor
05/24
05/24
INBRX-121 / Inhibrx Biosci
No trials found
INBRX-130 / Inhibrx Biosci
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SAR447537 / Sanofi
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Active, not recruiting
2
99
Europe, US, RoW
SAR447537, Zemaira, Respreeza
Sanofi
Alpha 1-Antitrypsin Deficiency, Emphysema
08/25
10/25
ELEVAATE OLE, NCT05897424: Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Recruiting
2
130
Europe, US, RoW
SAR447537
Sanofi
Alpha 1-Antitrypsin Deficiency, Emphysema
06/28
09/28
ozekibart (INBRX-109) / Inhibrx Biosci
2021-002635-35: A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarcoma). Estudio de fase 2, de INBRX-109 en adultos en un tipo de cancer de huesos y articulaciones irresecable o metastasico (condrosarcoma convencional)

Not yet recruiting
2
201
Europe
Desametasone, Difenidramina, INBRX-109, INBRX-109, Lyophilisate for solution for infusion
Inhibrx, Inc., Inhibrx, INC, Inhibrx, Inc.
Unresectable or metastatic conventional chondrosarcoma condrosarcoma convencional irresecable o metastásico., Malignant bone tumor that cannot be resected or it has been spread from the primary site (place where it started) to other places in the body. Tumor óseo maligno que no puede ser resecado o que se ha extendido desde el sitio primario (lugar donde comenzó) a otros lugares del cuerpo., Diseases [C] - Cancer [C04]
 
 
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
enristomig (INBRX-105) / Inhibrx Biosci
NCT03809624: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Terminated
1
160
US
INBRX-105 - PDL1x41BB antibody, Pembrolizumab, Keytruda
Inhibrx Biosciences, Inc
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
10/24
10/24
INBRX-106 / Inhibrx Biosci
HexAgon-HN, NCT06295731: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Recruiting
2/3
410
Europe, US, RoW
INBRX-106, Hexavalent OX40 agonist antibody, Pembrolizumab, Keytruda
Inhibrx Biosciences, Inc
Head and Neck Squamous Cell Carcinoma (HNSCC)
05/29
05/29
NCT06353997: Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

Recruiting
2
12
US
Pembrolizumab, KEYTRUDA, INBRX-106
Providence Health & Services, Inhibrx Biosciences, Inc
Triple Negative Breast Cancer
06/27
06/29
NCT06623136: A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

Recruiting
2
40
RoW
ES102, Toripalimab
Elpiscience (Suzhou) Biopharma, Ltd.
Non-Small Cell Lung Cancer
02/27
12/27
KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting
1/2
333
US
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, KEYTRUDA, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Alimta®, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2
Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
02/26
05/26
NCT04730843: A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors

Completed
1
18
RoW
ES102
Elpiscience Biopharma, Ltd.
Solid Tumors, Neoplasms, Malignant Tumor
03/24
03/24
NCT04991506: A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Completed
1
30
RoW
ES102, JS001, Toripalimab
Elpiscience Biopharma, Ltd., Shanghai Junshi Bioscience Co., Ltd.
Solid Tumor, Neoplasms, Malignant Tumor
05/24
05/24
INBRX-121 / Inhibrx Biosci
No trials found
INBRX-130 / Inhibrx Biosci
No trials found

Download Options